{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"The Deauville five-point scale was used to assess the number of participants with complete response (CR) and partial response (PR). A lower score indicates a better outcome. Scores of 1-3 represent CR and 4-5 represent PR.","groups":[{"description":"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.\n\nBrentuximab Vedotin: Given IV\n\nGemcitabine Hydrochloride: Given IV","id":"OG000","title":"Treatment (Brentuximab Vedotin, Gemcitabine Hydrochloride)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All eligible patients in phase 1, dose level 2 (N=13). 3 patients in phase 1 were not given dose level 2.","reportingStatus":"POSTED","timeFrame":"Up to 13 months from first dose","title":"The Number of Patients Who Had Disease Response Assessed by Deauville Scales Among Those in Phase I With Dose Level 2.","type":"SECONDARY","unitOfMeasure":"Participants"}